

Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Genotoxicity Testing (Revision 2)

VICH GL23(R2)

Guidance for Industry

Submit comments on this guidance at any time. Submit electronic comments to <https://www.regulations.gov>. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with docket number FDA-2000-D-0598.

For further information regarding this document, contact AskCVM@fda.hhs.gov

Additional copies of this guidance document may be requested from the Policy and Regulations Staff, Center for Veterinary Medicine, Food and Drug Administration, 5001 Campus Drive, College Park, MD 20740, and may be viewed on the Internet at <https://www.fda.gov/animal-veterinary>, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>, or <http://www.regulations.gov>.

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Veterinary Medicine (CVM)
September 2026**



International Cooperation on Harmonisation of Technical Requirements
for Registration of Veterinary Medicinal Products

VICH GL23 (R2) (SAFETY) – GENOTOXICITY

August 2025

Revision at Step 9

For implementation at Step 7

STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENOTOXICITY TESTING (REVISION 2)

Revision at Step 9

Recommended for Implementation
in August 2025
by the VICH Steering Committee

This Guideline has been developed by the appropriate VICH Expert Working Group and is subject to consultation by the parties, in accordance with the VICH Process. At Step 7 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.

Table of Contents

1.	Introduction.....	1
1.1.	Objective of the Guidance.....	1
1.2.	Background	1
1.3.	Scope of the Guidance	2
2.	Standard Battery of Tests	2
2.1.	A test for gene mutation in bacteria.....	3
2.2.	An <i>in vitro</i> test in mammalian cells.....	3
2.3.	An <i>in vivo</i> test for chromosomal effects using rodent hematopoietic cells	3
2.4.	A second <i>in vivo</i> genotoxicity test.....	3
3.	Modifications to the Standard Battery	3
3.1.	Antimicrobials.....	4
3.2.	Metabolic activation.....	4
4.	Overview of Recommended Tests.....	4
4.1.	A test for gene mutation in bacteria.....	5
4.2.	<i>In vitro</i> tests for chromosomal effects in mammalian cells.....	5
4.3.	<i>In vitro</i> tests for gene mutation in mammalian cells	5
4.4.	<i>In vivo</i> tests for chromosomal effects	6
4.5.	Second <i>in vivo</i> test for chromosomal effects.....	6
4.6.	Integration of <i>in vivo</i> genotoxicity testing in repeat-dose toxicity studies.....	6
5.	Evaluation of Tests Results	6
6.	References.....	7

Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Genotoxicity Testing (Revision 2)

Guidance for Industry

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.

1. Introduction

1.1. Objective of the Guidance

In order to establish the safety of veterinary drug residues in human food, a number of toxicological evaluations are recommended, including investigation of possible hazards from genotoxic activity. Many carcinogens and/or genotoxicants have a genotoxic mode of action, and it is prudent to regard genotoxicants as potential carcinogens unless there is convincing evidence that this is not the case. The results of genotoxicity tests will normally not affect the numerical value of an acceptable daily intake (ADI), but they may influence the decision on whether carcinogenicity tests are needed and whether an ADI can be established.

The objective of this guidance for industry (GFI) is to ensure international harmonization of genotoxicity testing of veterinary drug residues.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

1.2. Background

This guidance is one of a series of International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) guidances developed to facilitate the mutual acceptance of safety data necessary for the establishment of ADIs for veterinary drug residues in human food by the relevant regulatory authorities. It should be read in conjunction with the guidance on the overall strategy for the evaluation of veterinary drug residues in human food (Ref. [1](#)). GFI #116 (VICH GL23(R2)) was developed after consideration of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidances for pharmaceuticals for human use: "S2B Genotoxicity: A Standard Battery of Genotoxicity Testing of Pharmaceuticals" (Ref. [2](#)) and "S2A Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals" (Ref. [3](#)).

Contains Nonbinding Recommendations

For GFI #116 (VICH GL23(R2)), account is taken of Organisation for Economic Cooperation and Development (OECD) Guidelines for Testing of Chemicals; of the World Health Organization (WHO) International Programme on Chemical Safety (IPCS) Environmental Health Criteria (EHC) 240 (Ref. [4](#)); of ICH guidance S2(R1) (Ref. [5](#)); of a European Food Safety Authority (EFSA) opinion in 2011 (Ref. [6](#)); and of national/regional guidelines and the current practices for evaluating the safety of veterinary drug residues in human food in the European Union (EU), Japan, the United States of America Australia, Canada, New Zealand, and the United Kingdom. VICH seeks to minimize animal testing in alignment with the principle of the 3Rs – replacement, reduction, and refinement of animal use in toxicology studies. VICH therefore encourages the fullest possible implementation of the 3Rs principles and that these should be taken into account when planning studies.

1.3. Scope of the Guidance

This guidance recommends a Standard Battery of Tests that can be used for the evaluation of the genotoxicity of veterinary drug residues (including parent drug substances and/or metabolites). The Standard Battery of Tests intends to achieve reasonable confidence in the assessment of the genotoxicity potential of veterinary drug residues and to be in harmony with the requirements of ICH for testing human drugs for genotoxicity. This guidance also advises on modifications to the Standard Battery of Tests and on interpretation of test results.

2. Standard Battery of Tests

VICH recommends two options for the Standard Battery of Tests and both options are considered equally suitable for the hazard identification of genotoxicity potential:

- Option 1 includes a test for gene mutation in bacteria, an *in vitro* test in mammalian cells, and an *in vivo* test for chromosomal effects using rodent hematopoietic cells.
- Option 2 includes a test for gene mutation in bacteria, an *in vivo* test for chromosomal effects using rodent hematopoietic cells, and a second *in vivo* test.

In some jurisdictions, legislation requires implementation of the 3Rs wherever possible. Option 1 is therefore recommended unless there is scientific justification for using Option 2, or the second *in vivo* test can be integrated into repeat dose tests without requiring the use of an increased number of animals.

The current versions of OECD test guidelines for genotoxicity should be used to guide the conduct of the tests.

In most cases, it is the parent drug substance that is tested. In some cases, one or more of the major metabolites that occur as residues in food may also be tested, especially when it is produced in the target species but not produced in the laboratory animal species, and/or it has structural alerts; major metabolites are those comprising ≥ 100 $\mu\text{g/kg}$ or $\geq 10\%$ of the total residue in a sample collected from the target animal species in the metabolism study (Ref. [7](#)). For some regions, testing other, non-major metabolites may also need to be considered, such as when the metabolite has structural alerts that are not present in the molecular structure of the parent drug.

Contains Nonbinding Recommendations

Salts, esters, conjugates, and bound residues are usually assumed to have similar genotoxic properties to the parent drug, unless there is evidence to the contrary.

In addition to the Standard Battery of Tests, other available information (such as *in silico* data and published literature) may provide additional evidence as part of the weight of evidence assessment for genotoxicity potential of veterinary drug residues. When performing the *in silico* (quantitative) structure-activity relationship ((Q)SAR) assessment, two complementary (Q)SAR methods, i.e., expert rule-based and statistical-based, should be used (Ref. [8](#)). Current (Q)SAR models are effective only for predicting bacterial mutagenicity (Ref. [8](#)).

2.1. A test for gene mutation in bacteria

The gene mutation test in bacteria is the first test in Options 1 and 2 of the Standard Battery of Tests. An extensive database has been built up for bacterial reverse mutation tests for gene mutation in strains of *Salmonella typhimurium* and *Escherichia coli*. However, the bacterial gene mutation test, while being an efficient test for detecting substances with inherent potential for inducing gene mutations, does not detect all substances with mutagenic potential.

2.2. An *in vitro* test in mammalian cells

The second test in Option 1 evaluates the potential of a substance to produce chromosomal effects. This can be evaluated using one of the following three tests: (1) an *in vitro* mammalian cell micronucleus test, which detects both clastogenicity and aneugenicity; (2) an *in vitro* chromosomal aberrations test using metaphase analysis, which detects clastogenicity; or (3) an *in vitro* gene mutation test in mammalian cells, which can detect both gene mutation and chromosomal damage.

2.3. An *in vivo* test for chromosomal effects using rodent hematopoietic cells

The third test in Option 1 and the second test in Option 2 is an *in vivo* test to ensure the detection of all potential genotoxicants. This could be either a micronucleus test or a chromosomal aberration test.

2.4. A second *in vivo* genotoxicity test

The third test in Option 2 could be either the *in vivo* mammalian alkaline comet assay or the *in vivo* transgenic mouse/rat mutation assay. Other validated *in vivo* tests, such as the Pig-a assay (Ref. [9](#)), may also be acceptable.

3. Modifications to the Standard Battery

For most substances, the Standard Battery of Tests should be sufficient for genotoxicity testing. In some instances, there may be a need for modifications to the choice of tests or to the protocols of the individual tests. A scientific justification should be given for not using the Standard Battery of Tests.

The physicochemical properties of a substance (e.g., pH, solubility, stability, and volatility) can

Contains Nonbinding Recommendations

sometimes make standard test conditions inappropriate. It is essential that due consideration is given before tests are conducted. Modified protocols should be used where it is evident that standard conditions will likely give a false negative or false positive result. The OECD Guidelines for Testing of Chemicals for the genotoxicity tests provide advice on the susceptibility of the individual tests to the physical characteristics of the test substance, as well as advice on compensatory measures that may be taken.

Alternative genotoxicity tests (e.g., other validated genotoxicity studies, including new approach methods) may be considered on a case-by-case basis; however, their use should be justified.

3.1. Antimicrobials

Bacteria may be susceptible to inhibition by antimicrobial substances. For such substances, it would be appropriate to perform a gene mutation test in bacteria using concentrations up to the limit of cytotoxicity in accordance with the respective OECD guidelines, and to supplement the bacterial test with an *in vitro* test for gene mutation in mammalian cells.

3.2. Metabolic activation

The *in vitro* tests should be performed in the presence and absence of a metabolic activation system. Metabolic activation systems other than the standard S9 mix from induced livers of rats may be used, such as human microsomal preparations or S9 mix from induced livers of hamsters. A scientific rationale should be given to justify the choice of an alternative metabolic activation system.

4. Overview of Recommended Tests

The tests of the Standard Battery in Options 1 and 2 are listed in the table below, with their respective OECD guidelines.

Table 1. Tests of the Standard Battery in Options 1 and 2.

Type	Test	Section number	Option 1	Option 2	OECD TG number
<i>In vitro</i>	Bacterial reverse mutation test	4.1	First test	First test	471
	Mammalian cell micronucleus test	4.2	Second test (one of these tests)		487
	Chromosome aberration test in mammalian cells	4.2			473
	Mammalian cell gene mutation test using <i>Hprt</i> and <i>xprt</i> genes	4.3			476
	Mammalian cell gene mutation test using thymidine kinase gene	4.3			490
<i>In vivo</i>	Mammalian erythrocyte micronucleus test	4.4	Third test (one of these tests)	Second test (one of these tests)	474
	Mammalian bone marrow chromosome aberration test	4.4			475

Contains Nonbinding Recommendations

	Mammalian alkaline comet assay	4.5		Third test (one of these tests)	489
	Transgenic rodent somatic and germ cell mutation assay	4.5			488

4.1. A test for gene mutation in bacteria

A bacterial reverse mutation test should be performed according to OECD Test Guideline 471 (Ref. [10](#)). This test uses at least five amino acid-requiring strains of *S. typhimurium* and *E. coli* to detect point mutations by base substitutions or frameshifts. It detects mutations which revert “lack of function” mutations present in the test strains and restore the functional capability of the bacteria to synthesize essential amino acids and to allow bacterial growth without supplementation of the amino acid.

4.2. *In vitro* tests for chromosomal effects in mammalian cells

An *in vitro* mammalian cell micronucleus test should be performed according to OECD Test Guideline 487 (Ref. [11](#)). This test is a genotoxicity test for the detection of micronuclei in the cytoplasm of interphase cells. Micronuclei may originate from acentric chromosome fragments (i.e., lacking a centromere), or whole chromosomes that are unable to migrate to the poles during the anaphase stage of cell division. The assay detects the activity of clastogenic and aneugenic test substances in cells that have undergone cell division during or after exposure to the test substance. This test would be recommended for the detection of aneuploidy and, thus, as the preferred test for clastogenicity.

An *in vitro* chromosome aberration test should be performed according to OECD Test Guideline 473 (Ref. [12](#)). This test identifies substances that cause structural chromosomal aberrations from clastogenic events in cultured mammalian cells. Structural aberrations may be of two types: at chromosome level, or at chromatid level. Polyploidy (including endoreduplication) could arise in chromosome aberration assays *in vitro*. While aneugens can induce polyploidy, polyploidy alone does not indicate aneugenic potential and can simply indicate cell cycle perturbation or cytotoxicity. This test is not designed to measure aneuploidy.

4.3. *In vitro* tests for gene mutation in mammalian cells

A mammalian cell gene mutation test using *Hprt* and *xprt* genes should be performed according to OECD Test Guideline 476 (Ref. [13](#)). This test can be used to detect gene mutations. In this test, the genetic endpoints used measure mutation at hypoxanthine-guanine phosphoribosyl transferase (HPRT), and at a transgene of xanthine-guanine phosphoribosyl transferase (XPRT). The HPRT and XPRT mutation tests detect different spectra of genetic events.

A mammalian cell gene mutation test using the thymidine kinase (TK) gene should be performed according to OECD Test Guideline 490 (Ref. [14](#)). This test can be used to detect gene mutations. The Test Guideline includes two alternative *in vitro* mammalian gene mutation assays requiring two specific TK heterozygous cells lines: L5178Y TK^{+/−}3.7.2C

Contains Nonbinding Recommendations

cells for the mouse lymphoma assay (MLA) and TK6 $TK^{+/-}$ cells for the TK6 assay. Genetic events detected using the *tk* locus include both gene mutations and chromosomal events.

4.4. *In vivo* tests for chromosomal effects

The mammalian *in vivo* micronucleus test as described in OECD Test Guideline 474 (Ref. [15](#)) is used for the detection of damage to the chromosomes or the mitotic apparatus of erythroblasts by analysis of erythrocytes, which are sampled in bone marrow and/or peripheral blood cells of the test animals, usually rodents (mice or rats). This test identifies substances that cause cytogenetic damage which results in the formation of micronuclei containing lagging chromosome fragments or whole chromosomes. This test can be integrated into repeat-dose toxicity studies.

The mammalian *in vivo* chromosome aberration test, as described in OECD Test Guideline 475 (Ref. [16](#)), detects structural chromosome aberrations induced by test substances in bone marrow cells of the test animals, usually rodents (mice or rats).

4.5. Second *in vivo* test for chromosomal effects

The *in vivo* mammalian alkaline Comet assay (also called *in vivo* alkaline single cell gel electrophoresis assay), as described in OECD Test Guideline 489 (Ref. [17](#)), identifies substances that cause DNA damage. Under alkaline conditions, this assay can detect single and double stranded breaks. This test can be integrated into repeat-dose toxicity studies.

The transgenic rodent somatic and germ cell mutation assay, as described in OECD Test Guideline 488 (Ref. [18](#)), detects gene mutations in both somatic and germ cells. In this assay, transgenic rats or mice that contain multiple copies of chromosomally integrated plasmid or phage shuttle vectors are used as the test system. The transgenes contain reporter genes for the detection of various types of mutations induced by test substances during a 28-day treatment period.

4.6. Integration of *in vivo* genotoxicity testing in repeat-dose toxicity studies

VICH recommends combining the *in vivo* tests described above with repeat-dose toxicity studies, whenever possible. Further guidance can be found in ICH S2(R1) (Ref. [5](#)), IPCS (Ref. [4](#)), and OECD Test Guideline 474 (Ref. [15](#)).

5. Evaluation of Tests Results

The evaluation of the genotoxic potential of a substance should take into account the totality of the findings and acknowledge the intrinsic values and limitations of both *in vitro* and *in vivo* tests. Other available information (such as *in silico* data and published literature) may provide additional evidence as part of the weight of evidence assessment for genotoxicity potential of veterinary drug residues (Ref. [4](#)).

Clearly negative results for genotoxicity in a series of tests, including the Standard Battery of Tests, will usually be taken as sufficient evidence of an absence of genotoxicity.

Contains Nonbinding Recommendations

If a substance gives a clearly positive result for mutagenicity in the bacteria gene mutation test, additional *in vivo* testing including carcinogenicity tests may be needed. In some jurisdictions, the consequences of positive findings in genotoxicity tests are regulated in legislation (Ref. [19](#)).

If a substance gives clearly positive result(s) for *in vitro* genotoxicity tests, but a clearly negative result in the *in vivo* genotoxicity test(s) such as those performed using bone marrow, it will be necessary to confirm whether it is genotoxic with another *in vivo* genotoxicity test using a target tissue other than bone marrow. The most appropriate test should be chosen with justification on a case-by-case basis.

If a clear conclusion cannot be reached with the Standard Battery of Tests, follow-up considerations and strategies can be found through ICH (Ref. [5](#)), IPCS (Ref. [4](#)), and OECD (Ref. [20](#)).

6. References

1. Guidance for Industry #149 (VICH GL33), “[Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Testing](#),” (March 2009).
2. Guidance for Industry (ICH S2B), “[Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals](#),” (November 1997).
3. Guidance for Industry (ICH S2A), “[Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals](#),” (April 1996).
4. International Programme on Chemical Safety (IPCS). 2009. Environment Health Criteria (EHC) 240. Principles and methods for the risk assessment of chemicals in food. 2nd Edition. [Section 4.5 Genotoxicity](#), **updated in 2020**. Food and Agriculture Organization of the United Nations and World Health Organization. (Accessed July 31, 2024.)
5. Guidance for Industry (ICH S2(R1)), “Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use,” (June 2012).
6. European Food Safety Authority (EFSA). 2011. Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment. EFSA Journal 2011;9(9):2379.
7. Guidance for Industry #205 (VICH GL46), “Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-producing Animals: Metabolism Study to Determine the Quantity and Identify the Nature of Residues,” (September 2011).
8. Guidance for Industry (ICH M7(R2)), “Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk,” (July 2023).
9. OECD (2022). *Test No. 470: Mammalian Erythrocyte Pig-a Gene Mutation Assay*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/4faea90e-en> (accessed on July 11, 2025).

Contains Nonbinding Recommendations

10. OECD (2020), *Test No. 471: Bacterial Reverse Mutation Test*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/9789264071247-en> (accessed on July 31, 2024).
11. OECD (2023), *Test No. 487: In Vitro Mammalian Cell Micronucleus Test*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/9789264264861-en> (accessed on July 31, 2024).
12. OECD (2016), *Test No. 473: In Vitro Mammalian Chromosomal Aberration Test*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/9789264264649-en> (accessed on July 31, 2024).
13. OECD (1997), *Test No. 476: In vitro Mammalian Cell Gene Mutation Test*, OECD Publishing, Paris, <https://doi.org/10.1787/9789264071322-en> (accessed on July 31, 2024).
14. OECD (2016), *Test No. 490: In Vitro Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/9789264264908-en> (accessed on July 31, 2024).
15. OECD (2016), *Test No. 474: Mammalian Erythrocyte Micronucleus Test*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/9789264264762-en> (accessed on July 31, 2024).
16. OECD (2016), *Test No. 475: Mammalian Bone Marrow Chromosomal Aberration Test*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/9789264264786-en> (accessed on July 31, 2024).
17. OECD (2016), *Test No. 489: In Vivo Mammalian Alkaline Comet Assay*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/9789264264885-en> (accessed July 31, 2024).
18. OECD (2022), *Test No. 488: Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, <https://doi.org/10.1787/9789264203907-en> (accessed July 31, 2024).
19. European Union. 2018. Commission (EU) Regulation 2018/782 establishing the methodological principles for the risk assessment and risk management recommendations referred to in Regulation (<https://eur-lex.europa.eu/eli/reg/2018/782/oj>) (accessed on July 31, 2024).
20. OECD (2017), *Overview of the set of OECD Genetic Toxicology Test Guidelines and updates performed in 2014-2015 - Second edition*, OECD Series on Testing and Assessment, No. 238, OECD Publishing, Paris, <https://doi.org/10.1787/61eca5cd-en> (accessed on July 31, 2024).